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Abstract Calculations are presented for the pH-dependence of
stability and membrane charge complementarity of prion protein
fragments. The theoretical results are compared with reported
characterisations of prion protein folding in vitro. Discussion of
models for conformational change and pathogenesis in vivo leads
to the prediction of amino acids that could mediate sensitivity to
the endosomal pH and to a design strategy for recombinant prion
proteins with an increased susceptibility to prion proteinSc-like
properties in vitro. In this model, the protective effect of certain
basic polymorphisms can be interpreted in terms of oligomerisa-
tion on a negatively-charged surface.
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1. Introduction
Whilst the precise nature of the infectious agent in trans-
missible spongiform encephalopathies (TSEs) remains un-
known [1], a large amount of data implicate the protease
resistant form of PrP [2], denoted PrPSc in contrast to the
cellular protease-sensitive form, PrPC. Models to account for
pathogenesis within a protein-only framework have focussed
on conformational di¡erences between PrPC and PrPSc, par-
ticularly an increase in the L-sheet content in PrPSc [3]. Two
prominent models are those of conformational change within
a PrPC/PrPSc heterodimer [4] and of seeded polymerisation, in
which a PrPSc polymer grows from a population of individual
PrP molecules that £uctuate between PrPC and PrPSc states
[5]. The two models can be combined if PrPC is postulated to
bind to a PrPSc polymer prior to conformational conversion
[6]. The relative infectivity of TSEs compared with other amy-
loidoses [1] would be consistent with the recruitment of an
evolved interaction. For example, a PrPC/PrPSc heterodimer
could exchange monomers between PrPC and PrPSc homo-
dimers, with the PrPSc homodimer cross-linked to a polymer
through a separate interaction [7].
Solution structures have been reported for a fragment 121^
231 and full length 23^231 recombinant mouse PrP (MoPrP)
[8,9] and for a larger fragment 90^231 and full length 29^231
recombinant Syrian hamster PrP (SHaPrP) [10,11]. The fold
of PrP(121^231) is consistent between these studies, presum-
ably re£ecting the core PrPC structure. The amino-terminal
region, containing the peptide repeat that binds copper in
vitro [12] and in vivo [13], is mobile in these reports. This
region is not required for PrPSc propagation [14]. The solution
structures provide a starting point for modelling the PrPC/
PrPSc conversion that is likely to feature in many forms of
PrP-related neurodegenerative disease, although disease-caus-
ing mutations can also be associated with an altered PrP
translocation in the endoplasmic reticulum [15].
This article considers predictions of pH-dependence for
MoPrP(121^231) and for HuPrP(90^231) modelled from
SHaPrP(90^231), alongside unfolding characterisations that
have identi¢ed a L-rich intermediate in the presence of dena-
turant at an acidic pH [16,17]. The predicted pH-dependence
supplies hypotheses that can be tested by mutagenesis. Calcu-
lations of PrP complementarity with a negatively-charged
membrane surface are added in considering the potential in-
volvement of PrP-membrane and PrP-PrP interactions in the
prion pathogenesis, including discussion of the protective ef-
fects of certain basic polymorphisms in terms of possible
membrane-induced stabilisation of PrPC rather than interac-
tions with a protein X [18].
2. Materials and methods
2.1. PrP structures
Solution structures were obtained from the Protein Data Bank,
1ag2 for MoPrP(121^231) [8,19] and 2prp for SHaPrP(90^231) [10].
The 1ag2 set contains a single re¢ned conformer. A model for
HuPrP(90^231) was constructed from conformer seven of the unre-
¢ned SHaPrP(90^231) coordinates, with 18 amino acid changes (eight
involving ionisable groups), with the program QUANTA (Molecular
Simulations). Additional sidechain torsions were applied to alleviate
close contacts for ionisable residues. The HuPrP(90^231) model main-
tains the 3D framework of the SHaPrP(90^231) structure.
2.2. Calculations of the pH-dependence
Charge-charge interactions were calculated with the Debye-Hu«ckel
(DH) method, using a uniform relative dielectric of 80 and a ionic
strength at 0.15 M. This model is more robust in overall comparisons
to experimental pKas than are current implementations of more de-
tailed methods that incorporate a lower dielectric response, since most
ionisable group interactions are dominated by solvent-like dielectric
properties [20]. Calculations included R, K, H, D and E residues, as
well as the N- and C-terminal groups of the HuPrP(90^231) model.
The two cysteines (179 and 214 in human PrP) are disul¢de-bonded
and tyrosine ionisation has been omitted in this study which concen-
trates on neutral and acidic pH. Polar hydrogen atoms were retained
and non-polar hydrogen atoms removed from the coordinates and
ionisable group and partial charges [21] assigned. A statistical treat-
ment of interacting groups was used for pKa calculations [22]. The
pH-dependence of vGNU, the free energy di¡erence between native
and unfolded states, was calculated with DH application to the native
PrP structures and to a simple model for ionisable group interactions
in the unfolded form. This model gives a signi¢cantly improved match
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to the experiment, based largely on nearest neighbour ionisable resi-
due interactions in the unfolded state [20].
2.3. Calculation of PrP-membrane charge interactions
A program was written to assess the complementarity between PrP
charges and a negatively-charged surface, such as a phospholipid
membrane. The planar surface contacts the protein at tangents to
radii that describe a sphere. In each orientation, the interaction was
summed over groups carrying a net charge. Each charge, at distance z
from the membrane, interacts with a potential x=x0exp(3Uz), with
x0 =c/(OO0U), where U is the Debye-Hu«ckel factor (at 0.15 M ionic
strength), O0 is the zero permittivity, O is the relative dielectric (80) and
c is the surface charge density (77 Aî 2 for each negative charge).
Interactions were contoured on a spherical shell for display in the
program QUANTA running on a Silicon Graphics workstation.
These calculations are empirical, with a smeared membrane charge
and without optimisation of protein sidechain-membrane interactions.
A similar analysis for non-polar interactions is more di⁄cult since
solvent accessible area is highly dependent on a conformational detail
that is not well-de¢ned in this model.
3. Results and discussion
3.1. Calculations of the pH-dependence
Fig. 1A shows the calculated acid pH-dependence of vGNU
for HuPrP(90^231) that has been modelled from SHa(90^
231). For this fragment, vGNU =319 kJ/mol at a neutral
pH (measured in guanidinium hydrochloride, GuHCl), with
a native-like secondary structure down to pH 2.6 in the ab-
sence of denaturant, but an only marginal stability to GuHCl
at pHs 2.6, 3.6 and 4.0 [16]. The pH-dependence calculations
are consistent with these data, with a marginal stability at a
low pH, supporting their use in predictive modelling.
The non-polar surface area is exposed in HuPrP(90^231) in
a process with a pKa of about 5.1 that does not involve global
loss of the native-like secondary structure [16]. Since 90^120 is
relatively mobile in the SHaPrP(90^231) solution structure, it
is likely that the native secondary structure is associated with
the 121^231 folding core and that the non-polar surface ex-
posure relates to a change in the average properties of the 90^
120 segment. Such a change would be consistent with the
reported contrast between the sensitivity of SHaPrP(90^231)
to solution conditions around pH 5.2 and the lower pH of 4.5
for the MoPrP(121^231) structure [10]. Candidate ionisable
groups for mild acidic pH transitions present in PrP(90^
231), but apparently absent in PrP(121^231), are clear. Both
HuPrP and SHaPrP have two histidine and four lysine resi-
dues within 90^120. Only H-96 and H-111 have calculated
pKas between 5 and 6 in HuPrP(90^231) and sequence con-
siderations alone suggest that the basic charge concentration
could push these histidine pKas towards a mild acidic pH. If
the highly-conserved segment within 90^128 mediates func-
tional PrPC-PrPC interactions, then, such histidine pKas could
determine the oligomeric status at a mild acidic pH [6], per-
haps linking to titration of copper-octarepeat binding at
about pH 6 [23] if an acidic intracellular (endosomal) com-
partment is involved. It is therefore suggested that mutation
of H-96 and H-111 could probe the pH-dependence both in
vitro and in vivo.
The L-rich intermediate that appears at a mild acidic pH in
the presence of denaturant involves a signi¢cant structural
change in the 121^231 folding core [17]. For MoPrP(124^
226), the resolved polypeptide in the MoPrP(121^231) struc-
ture, Fig. 1B gives calculated pH-dependences for the GN and
GU components of vGNU. These are separated by the meas-
ured vGNU (urea denaturation) of 328.6 kJ/mol at a neutral
pH [17]. Again, the calculations are consistent with the meas-
ured PrP fragment stability at acidic pH. The L-rich inter-
mediate, which complicates the comparison of theory and ex-
periment for vGNU at an acidic pH, is viewed as a potential
link to PrPSc. Fig. 1B shows schematically a plausible overall
relationship between native, unfolded and intermediate state
stabilities. Intermediate (I) appears at pH 5 in the presence of
denaturant, indicating a stability between N and U, whilst
increasing I as the pH is lowered to 4 in the absence of de-
naturant [17], suggesting a hypothetical N/I intercept that is
drawn at pH 3.5 (this intercept occurs at a lower pH for
HuPrP(90^231), which has a native-like secondary structure
at pH 2.6 [16]). The simple observation is that experimental
characterisations of a L-rich intermediate are consistent with a
scheme in which the acid pH-dependence of the stability is
signi¢cantly less for I than for N and that we can therefore
use the predicted GN to look at factors that may contribute to
I formation at an acidic pH.
Fig. 1. Calculated acid pH-dependence for PrP fragments. A: The
predicted vGNU for modelled HuPrP(90^231) is ¢xed at the meas-
ured neutral pH value, vGNU =319 kJ/mol [16]. B: The predicted
pH-dependence of MoPrP(124^226) GN and GU are shown with an
arbitrary overall origin and separated by 328.6 kJ/mol at pH 7
[17]. The schematic I plot shows a possible L-rich intermediate pH-
dependence in the indicated pH range (see Section 3). C: Calculated
D, E and H vpKas in native MoPrP(124^226) are displayed in the
context of the secondary structure [19].
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The predicted acid pH-dependence of GN (and GU) arises
largely from diminishing favourable interactions as D/E resi-
dues bind protons at pH6 5. Fig. 1C shows the calculated
vpKas of D, E and H residues within native MoPrP(124^
226). Signi¢cant negative vpKas (denoting N stabilisation at
a neutral pH), are located in K1 and the K2-K3 segment. The
large vpKa (31.06) at the start of K2 relates to the pathogenic
mutation D178N. The calculated vpKa of E200 is only 30.23,
since this sidechain extends into solvent rather than forming a
helix N-cap in the solution structure [19], with the E200K
charge reversal predicted to give just one half of the D178N
e¡ect. Computed destabilisation of E200K relative to wild-
type by about 3 kJ/mole is in good agreement with a recently
reported experimental determination of 4 kJ/mole [24]. It ap-
pears generally that some pathogenic PrP mutations may be
linked predominantly to native state destabilisation, whilst
others will require a more detailed understanding of the con-
version process and PrPSc structure [25]. The extent of pH-
dependence in N, U and I could be assessed from measure-
ments of proton titration over accessible acidic pH ranges for
wild-type and mutant PrPs.
Calculations of energy di¡erences, for example relating to
pathogenic mutations, are hampered by a lack of structural
information for PrPSc. In addition, the L-rich intermediates
characterised in vitro [16,17] do not form L-cross-links be-
tween molecules [3], suggesting the involvement of other com-
ponents in vivo. However, these intermediates are of signi¢-
cant interest and the current modelling highlights the potential
role and relative e¡ects of acidic residues in the folding core.
The calculations are inconsistent with the substantial increase
in the MoPrP(121^231) stability from pH 7 to pH 4.5 that
would be obtained from comparison of vGNU =328.6 kJ/mol
to the sum of vGNI (331.1 kJ/mol) and vGIU (322.4 kJ/mol)
at pH 4.5 [17]. Assumptions involved in vG extrapolation to a
zero denaturant concentration, complicated by the three-state
system, may contribute to this discrepancy.
3.2. Calculation of PrP-membrane charge complementarity
Fig. 2A shows modelled MoPrP(124^226) interactions with
an anionic membrane surface at neutral pH and with a net
protein charge of 30.5e. A positively-charged PrP face and its
potential for membrane interactions has been noted previ-
ously [8]. The current calculation shows a clearly-de¢ned con-
tiguous set of favourable binding orientations. The blue arrow
denotes membrane binding to the positively-charged face that
includes helix K1. At right angles, the yellow arrow points into
the fragment N-t. Considerations of polarity, conservation
and species barriers gave rise to the suggestion that PrP could
interact with the membrane surface in either of these orienta-
tions [7]. This suggestion is now re¢ned with the reported
speci¢city of inhibition of the in vitro conversion reaction
with respect to peptides within 106^141 and residues G119
and A120 in particular [26]. Such a speci¢city implies a pro-
tein-peptide interaction so that a single overall PrP-membrane
orientation is now favoured, with the region adjacent to the
N-t at 124 (yellow arrow) mediating protein-protein interac-
tions and putative membrane binding to the K1-containing
face (blue arrow). The right angle indicates that symmetric
PrP-PrP interactions could occur across the membrane sur-
face. Whilst PrPC is readily released from a membrane by
cleavage of its glycosylphospatidylinositol anchor [27], the
calculations suggest that PrP-membrane charge interactions
could in£uence the PrP orientation through summation in
an aggregate.
3.3. Modelling interaction domains within PrP(90^231)
Predictions of the pH-dependence and PrP-membrane inter-
actions are considered in the context of data relating to PrPC/
Fig. 2. Modelling interaction domains in PrP. A: Calculated charge
complementarity of MoPrP(124^226) [19] with a negatively-charged
membrane. The white contour shows favourable interactions at a
level of 320 kJ/mol, with the membrane lying at a tangent to each
shell radius. The blue arrow denotes a potential membrane binding
face and yellow and white arrows denote potential PrP-PrP interac-
tion domains shown also in B. The view is along helix 3, the cross-
section of which appears in yellow. B: A view onto the top of a pu-
tative PrP-membrane complex shows in white the three segments of
a PrPSc-speci¢c epitope [29], whilst the yellow schematic 90^123 seg-
ment adjoins the MoPrP(124^226) fragment N-t and occupies a sim-
ilar region to the relatively labile equivalent part in the SHaPrP(90^
231) structure [10]. Blue stripes show the disul¢de-bonded residues
C-179 and C-214 and purple marks the human polymorphic site
129. Red markers give the eight residues of Fig. 1C that have
vpKa630.3: D-144, E-146, D-147, E-152, D-178, E-196, D-202
and E-211.
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PrPSc conformational changes [28,29] and protein X binding
[18]. Fig. 2B looks onto a potential PrP-membrane complex
(into the blue arrow of Fig. 2A). Proposed membrane binding
to the K1-containing face and PrP-PrP binding involving the
conserved non-polar segment gives two interaction domains.
The speci¢city of interactions involving the latter region [26]
may re£ect PrPC/PrPSc interactions that are recruited from
PrPC/PrPC [6]. This segment is not necessary for formation
of the in vitro L-rich intermediate [17] and it is labelled the
initial binding domain.
The three segments of a PrPSc-speci¢c epitope, that is com-
mon in BSE, scrapie and CJD, presumably become neigh-
bours in PrPSc [29]. This could occur with a dimeric or
approximately dimeric interaction on the membrane sur-
face, with symmetry-related 214^226/162^170 adjacent to
142^148, suggesting that this part of PrP could form a third
interaction domain (Fig. 2B). Taken together, these three do-
mains could mediate membrane-templated PrP polymer for-
mation. Siting of species barrier residues in the highly-con-
served segment and at 139 (human PrP numbering) [30] is
consistent with dimeric interactions across both proposed
PrP-PrP interaction domains. Of the eight D and E residues
with predicted vpKas630.3 in native MoPrP(124^226), four
are located around the 142^148 segment and two are adjacent
to the 214^226 and 162^170 segments (Fig. 2B). Stabilisation
of D/E residues in K1 arises from interactions with the basic
residues that determine the membrane charge complementar-
ity. These D/E locations suggest that the PrPSc-speci¢c epitope
may be associated with a conformational change during the in
vitro N/I transition and possibly the PrPC/PrPSc conversion.
Proposed cross-linking, mediated by this domain, may there-
fore be concomitant with a conformational change.
Involvement of the 214^226 segment in conversion would
not necessarily preclude antibody accessibility to 225^231 in
PrPSc and PrPC [28]. Equally, an epitope within 95^104 that is
exposed in PrPC and largely cryptic in PrPSc [28] does not
preclude PrPC/PrPSc di¡erences in other regions. In this mod-
el, di¡erent antibody reactivities with 95^104 would relate to
dimerisation across the conserved non-polar region that is
transient in PrPC, but longer lived in PrPSc due to the addition
of polymer cross-linking interactions associated with K/L-tran-
sition in more C-t regions.
Basic polymorphisms at sites (human PrP numbering) 168,
172, 215 and 219 that protect against conversion are thought
to form part of an epitope for protein X binding to PrP,
rendering it unavailable for prion propagation [18]. Calcula-
tions with the current model show that basic sidechains are
predicted to have varying e¡ects on the PrPC stability and
PrPC stability in the presence of a negatively-charged mem-
brane. Whilst Q168R is calculated to give intrinsic PrPC sta-
bilisation, basic residues at 215 or 219 could stabilise PrPC
through favourable interactions with the membrane. Such
modelling therefore suggests an alternative explanation for
the protective e¡ects of these basic polymorphisms, particu-
larly since these sites lie within regions of a proposed PrPC/
PrPSc conformational change. Not all basic substitutions
would necessarily have a native state stabilising e¡ect. For
example, the pathogenic mutation Q217R in humans [2] could
destabilise PrPC through loss of a hydrogen bond between the
sidechain amide and the mainchain carbonyl of A133 [19].
Biochemical strain-typing [31] is based on measurements of
protease resistance and glycoform levels in PrPSc. These could
relate to packing variations within a polymer formed on a
membrane (but probed after membrane solubilisation). The
human polymorphic residue 129 is sited between proposed
interactions domains (Fig. 2B) and could therefore in£uence
packing. Both N-linked glycosylation sites are exposed and
without steric restriction in the PrP-membrane complex of
Fig. 2B. Glycosylation generally stabilises proteins [32]. If
glycosylation stabilises PrPC and if the PrPC stability plays
a role in pathogenesis, then, in PrPSc seed formation (as op-
posed to propagation), it may be that sporadic TSEs would
incorporate a lower glycosylation (less stable PrPC) and that
those inherited TSEs that derive from PrPC destabilising mu-
tations would tend more towards the available range of gly-
cosylation. Propagation of glycoform levels could relate to
packing or size exclusion e¡ects that trace back to the seed.
The link between strain-typing by protease resistance and gly-
coform levels and by a bioassay and lesion pro¢ling is un-
known, but presumably entails the interaction of a region-
speci¢c cellular property, such as the PrPC production level
or rate of PrPSc clearance [2], with a PrPSc-speci¢c property.
One candidate for this latter property could be simply the
e¡ect of the PrPSc glycoform composition on the amount of
PrPC that is accepted for conversion.
3.4. Testing the model
The current model has been developed alongside existing
data and can be tested with further measurements. Mutation
of (human PrP numbering) H-96 and H-111 within PrP(90^
231) would probe any role in the process of non-polar surface
area exposure around pH 5.1 that does not involve global loss
of the native-like secondary structure [16]. The model predicts
that the conserved non-polar segment within 90^120 is crucial
to an initial binding step that precedes K to L structure con-
version. This hypothesised initial binding could be probed
with resolution of the order of binding and conversion, there-
by distinguishing this model and those that invoke conversion
before, or concomitant with, initial binding.
With respect to characterisation of the L-rich in vitro inter-
mediate, our calculations suggest that removal of a sidechain
negative charge at the following locations will destabilise PrPC
and potentially enhance the intermediate formation: 196, 178,
202, 152, 144, 147, 146, 211. This listing ranks the predicted
destabilisations from about 6 kJ/mole (196, 178) to about 2
kJ/mole (211). It would be of interest to assess whether the L-
rich intermediate is less accessible for PrP with N-linked gly-
cosylation.
The suggestion that the protective e¡ects of basic sidechains
at certain polymorphic sites could relate to PrPC stabilisation
in the presence of a membrane could be probed with measure-
ments of recombinant PrP interactions with a negatively-
charged surface, particularly the e¡ects of positive charges
at 215 and 219. A predicted membrane involvement in the
PrPSc formation could be studied with in vitro conversion
e⁄ciencies in the presence and absence of membrane compo-
nents.
The three modelled interaction domains (Fig. 2) suggest
strategies for designing recombinant PrPs with PrPSc-like
properties in the absence of the putative membrane templating
and for considering potential inhibitors of PrPSc formation.
Designed destabilisation of the proposed cross-linking (K/L
conversion) domain together with stabilisation of the pro-
posed initial dimerisation may increase the susceptibility to
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PrPSc formation. We have suggested that the membrane plays
a role in this putative dimerisation in vivo through biasing the
orientation and con¢guration, perhaps aided by the three con-
served lysine residues (101, 104, 106) on the N-t side of the
non-polar segment. Dimerisation without membrane may
therefore be enhanced by the introduction of an adjacent
complementary acidic patch on PrP or by a cross-linking
strategy that brings together the non-polar segments of two
PrP molecules. The model suggests that polyanionic inhibitors
[33] could interact with the proposed membrane binding do-
main and that more e¡ective inhibitors of PrPSc formation
should link such an activity with elements targeted at sequen-
ces in the proposed dimerisation and cross-linking domains.
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